-
-
-
-
-
-
-
Takeda (TAK) Reports Phase 3 Topline Results for Soticlestat
-
-
-
-
-
-
-
Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
-
-
-
-
-
-
-
Takeda's (TAK) EXKIVITY Approved in China
-
-
-
-
-
-
-
Takeda (TAK) Announces EC Approval of LIVTENCITYTM
-
-
-
-
-
-
-
Takeda Pharmaceutical (TAK) Reports New Exploratory Analysis Showing Patients Treated With LIVTENCITY Had Reductions in Hospitalization Rates and Length of Hospital Stay
-
-
-
-
-
-
-
UPDATE: FDA AdCom Unanimously Recommends Use of Takeda's (TAK) Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection
-
-
-
67,416 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

